Yüklüyor......
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
PURPOSE: To estimate the budget impact of selinexor, bortezomib, and dexamethasone (XVd) in patients with previously treated multiple myeloma (MM) from the perspective of a private third-party payer and Medicare in the US. METHODS: The introduction of XVd as an option for patients with previously tr...
Kaydedildi:
| Yayımlandı: | Clinicoecon Outcomes Res |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8203300/ https://ncbi.nlm.nih.gov/pubmed/34140789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S305830 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|